Docetaxel vs Cabazitaxel for Prostate Cancer
(CABPOSTAAT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to compare two treatments, docetaxel and cabazitaxel, for men with metastatic castration-resistant prostate cancer (mCRPC). Researchers seek to determine if cabazitaxel, a chemotherapy drug, can extend the time patients live without cancer progression. Participants should have prostate cancer that has spread and worsened despite previous treatments such as docetaxel or abiraterone. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that docetaxel is usually well-tolerated, but some risks exist. One study found that 34% of patients taking docetaxel were hospitalized, mostly due to febrile neutropenia, a condition where fever occurs with low levels of a specific white blood cell. Despite these risks, docetaxel has improved survival rates in patients with prostate cancer.
Cabazitaxel serves as another treatment option, often used after docetaxel. Although specific safety details aren't available from the sources, its approval for similar uses suggests general safety. However, as this is a phase 2 study, the trial aims to learn more about patients' tolerance to cabazitaxel.
Both treatments show promise but carry some risks. Patients should discuss with their healthcare team to determine the best option for them.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for prostate cancer because both cabazitaxel and docetaxel offer unique benefits. While docetaxel is a well-established chemotherapy drug traditionally used for prostate cancer, cabazitaxel is gaining attention for its ability to overcome resistance seen in some patients who no longer respond to docetaxel. Cabazitaxel operates by disrupting cancer cell division in a slightly different way, potentially offering a fresh option for patients who have exhausted other treatments. Both drugs are paired with prednisone, which helps manage symptoms and enhance the effectiveness of the chemotherapy. This dual approach aims to improve outcomes for patients facing advanced stages of prostate cancer.
Who Is on the Research Team?
fred Saad, MD
Principal Investigator
CHUM
Are You a Good Fit for This Trial?
Men with advanced prostate cancer that has spread and worsened despite hormone therapy with abiraterone or enzalutamide. They must have a rising PSA level, measurable disease progression, effective castration (low testosterone), and be able to consent. Excluded are those who've had certain prior treatments, uncontrolled other cancers or medical conditions, severe side effects from past cancer therapies, or inadequate organ function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either cabazitaxel plus prednisone or docetaxel plus prednisone until disease progression, unacceptable toxicity, or refusal of further treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- Cabazitaxel
- Docetaxel
Cabazitaxel is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
Genzyme, a Sanofi Company
Industry Sponsor
David Meeker
Genzyme, a Sanofi Company
Chief Executive Officer since 2011
MD from the University of Vermont Medical School, Advanced Management Program at Harvard Business School
Jean-Paul Kress
Genzyme, a Sanofi Company
Chief Medical Officer since 2015
MD from Faculte Necker-Enfants Malades, Paris